Literature DB >> 17440679

The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors.

L-H Guo1, H J Schluesener.   

Abstract

Toll-like receptors (TLRs) are a family of pattern recognition receptors that mediate innate immune responses to stimuli from pathogens or endogenous signals. Under various pathological conditions, the central nervous system (CNS) mounts a well-organized innate immune response, in which glial cells, in particular microglia, are activated. Further, the innate immune system has emerged as a promising target for therapeutic control of development and persistence of chronic pain. Especially, microglial cells respond to peripheral and central infection, injury, and other stressor signals arriving at the CNS and initiate a CNS immune activation that might contribute to chronic pain facilitation. In the orchestration of this limited immune reaction, TLRs on microglia appear to be most relevant in triggering and tailoring microglial activation, which might be a driving force of chronic pain. New therapeutic approaches targeting the CNS innate immune system may achieve the essential pharmacological control of chronic pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440679     DOI: 10.1007/s00018-007-6494-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  46 in total

Review 1.  The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs.

Authors:  Haroon Hameed; Mariam Hameed; Paul J Christo
Journal:  Curr Pain Headache Rep       Date:  2010-04

Review 2.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

Review 3.  Glia in pathological pain: a role for fractalkine.

Authors:  E D Milligan; E M Sloane; L R Watkins
Journal:  J Neuroimmunol       Date:  2008-06-10       Impact factor: 3.478

Review 4.  Neuroinflammation and comorbidity of pain and depression.

Authors:  A K Walker; A Kavelaars; C J Heijnen; R Dantzer
Journal:  Pharmacol Rev       Date:  2013-12-11       Impact factor: 25.468

5.  Toll-like receptors in the depressed and suicide brain.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Xinguo Ren; Runa Bhaumik; Yogesh Dwivedi
Journal:  J Psychiatr Res       Date:  2014-02-11       Impact factor: 4.791

6.  Toll-Like Receptor Signaling Contributes to Proinflammatory Mediator Production in Localized Provoked Vulvodynia.

Authors:  Megan L Falsetta; David C Foster; Collynn F Woeller; Stephen J Pollock; Adrienne D Bonham; Dorota Piekna-Przybylska; Sanjay B Maggirwar; Constantine G Haidaris; Richard P Phipps
Journal:  J Low Genit Tract Dis       Date:  2018-01       Impact factor: 1.925

7.  Bilateral activation of glial cells and cellular distribution of the chemokine CCL2 and its receptor CCR2 in the trigeminal subnucleus caudalis of trigeminal neuropathic pain model.

Authors:  Lucie Kubíčková; Ilona Klusáková; Petr Dubový
Journal:  Histochem Cell Biol       Date:  2020-02-04       Impact factor: 4.304

8.  Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery.

Authors:  Miklos D Kertai; Yi-Ju Li; Yunqi Ji; Wenjing Qi; Frederick W Lombard; Svati H Shah; William E Kraus; Mark Stafford-Smith; Mark F Newman; Carmelo A Milano; Nathan Waldron; Mihai V Podgoreanu; Joseph P Mathew
Journal:  Am Heart J       Date:  2015-06-17       Impact factor: 4.749

9.  A peptide antagonist of the TLR4-MD2 interaction.

Authors:  Peter F Slivka; Mitesh Shridhar; Gui-in Lee; Deanne W Sammond; Mark R Hutchinson; Alexander J Martinko; Madison M Buchanan; Page W Sholar; Jeffrey J Kearney; Jacqueline A Harrison; Linda R Watkins; Hang Yin
Journal:  Chembiochem       Date:  2009-03-02       Impact factor: 3.164

Review 10.  Toll-like receptor 4 modulation as a strategy to treat sepsis.

Authors:  X Wittebole; D Castanares-Zapatero; P F Laterre
Journal:  Mediators Inflamm       Date:  2010-04-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.